Conference call for analysts and investors to be held on 23 February 2017 at 15:00 CET
IRVINE, CA, and HERSTAL, BELGIUM - February 9, 2017 - MDxHealth SA (Euronext: MDXH.BR) or the "Company" today announced that it will release its full year results for the financial year ended 31 December 2016 on Thursday 23 February 2017.
Dr. Jan Groen, Chief Executive Officer and Jean-Marc Roelandt, Chief Financial Officer, will host a conference call on the day of the results at 15:00 CET / 14:00 GMT / 06:00 PT. The call will be conducted in English and a replay will be available for 30 days.
To access the conference call, please dial one of the appropriate numbers below quoting the conference ID 69886101.
Belgium: +32 (0)81 70 00 61
The Netherlands +31 (0)8000 235 091
UK: +44 (0)1452 55 55 66
US: +1 (0)8669 669 439
The presentation will be made available on the Investors section of the MDxHealth website shortly before the call and can be accessed at: http://mdxhealth.com/investors.
To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled start timing.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
For more information:
| Dr. Jan Groen, CEO MDxHealth US: +1 949 812 6979 BE: +32 4 364 20 70 [email protected] Jean-Marc Roelandt, CFO MDxHealth US: +1 949 812 6979 BE: +32 4 364 20 70 [email protected] | Consilium Strategic Communications (IR & PR) Amber Fennell, Chris Welsh & Hendrik Thys UK: +44 20 3709 5701 US: +1 917 322 2571 (Rx Communications Group LLC) [email protected] |
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/48f3c927-9290-4ad9-87bd-44a689dc1a43


TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Instagram Outage Disrupts Thousands of U.S. Users
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



